CorriXR Therapeutics is on the clinical frontier of gene editing as a transformative pre-clinical stage biotechnology company with a ground-breaking in vivo gene editing therapeutic platform technology. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new genetic medicines directed against drug-resistant solid tumors.
Location: United States, Delaware, Newark
Employees: 1-10
Founded date: 2022
Investors 1
| Date | Name | Website |
| 09.02.2024 | Cortado Ve... | cortado.ve... |
Mentions in press and media 1
| Date | Title | Description |
| - | CorriXR Therapeutics | “CorriXR” |